www.fdanews.com/articles/148421-gilead-sciences-to-promote-low-cost-hiv-medicine-in-developing-world
Gilead Sciences to Promote Low-Cost HIV Medicine in Developing World
August 3, 2012
Gilead Sciences said it plans to partner with Mylan, Ranbaxy Laboratories and Strides Arcolab to promote access to high-quality, low-cost generic versions of Gilead’s HIV medicine emtricitabine in developing countries.
The Wall Street Journal
The Wall Street Journal